At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 87 enrolled
Drug / intervention
LY3484356drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
In Brief
A Phase 1 clinical trial evaluating LY3484356 for Breast Cancer. Completed, enrolled 87 participants across 19 sites in 6 countries.
Detailed Summary
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesBelgium, France, Germany, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartApr 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedDec 1, 2020
Enrollment StartApr 21, 2021
Primary CompletionNov 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.6 years ago
Interventions
LY3484356drug
Administered orally.